Top Markets
Coin of the day
Ultimovacs ASA Ultimovacs ASA

Ultimovacs ASA

ULTI
Rank in Stocks #34179
Ultimovacs ASA is a pharmaceutical company based in Oslo, Norway, established... Ultimovacs ASA is a pharmaceutical company based in Oslo, Norway, established in 2011. The firm specializes in developing immunotherapies to combat various cancers. Its main product in development is UV1, a peptide vaccine engineered to stimulate a T-cell immune response against telomerase, an antigen found widely across different cancer types.
Share Price
$0.17687105
Last synced: 2025-04-01
Market Cap
$6.08M
Change (1 day)
-89.96%
Change (1 year)
0.00%
Country
NO
Trade Ultimovacs ASA (ULTI)

Category

P/E ratio for Ultimovacs ASA (ULTI)
P/E ratio as of 2026 TTM: 0
According to Ultimovacs ASA latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Ultimovacs ASA from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
29.20 -
US
30.62 -
NL
- -
CH
- -
KR
18.38 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.